Therapeutic Effect of Rosiglitazone Combined with Adipose-Derived Stem Cell Transplantation in Rats with Type 2 Diabetes Mellitu
Total Page:16
File Type:pdf, Size:1020Kb
ęඈඋ1࣏ۘऺ ৰ 21 Ż ৰ 33 ƛ 20171128 ϦČ Chinese Journal of Tissue Engineering Research November 28, 2017 Vol.21, No.33 www.CRTER.org ऺƣጛۘ 2Ƨசɳ҉۔ปʸ′⍤༘Ȍ࿆¾ඊྡྷࢿΉ͏ћ̓ ăএ) ϴ ዐ(ǧSďS˂ˡŋʒ½ˍãKǧSď 300350) .Ƨசɳ҉[J].ęඈඋ1࣏ۘऺ 2017 21(33):5325-5331 2 ۔šϬƨăএ) ϴዐ. ปʸ′⍤༘Ȍ࿆¾ඊྡྷࢿΉ͏ћ̓ DOI:10.3969/j.issn.2095-4344.2017.33.013 ORCID: 0000-0001-9343-6732(ăএ)) তȷợⓉᪿ ÒŻűK˿K1973 ˝ÛK Ƨசɳ҉ 2 ۔ปʸ′⍤༘Ȍ࿆¾ඊྡྷࢿΉ͏ћ̓ ǧSďNK˩ȂKƶƍ åKƶϙÎāˍǫɯΡ~ ̼ϟūʃ Ƿ ͏ћȒ 3 ɬ Ě ିǻ:R394.2 ाွᜄ Ș۔ȭ+ඈ (1)ᢆȓȈඈ̓ B:ۅǒɀ¬ĭ Dzʃ (1)µƧඈ˸྇ǎɲ☝ ச3ྴˏ3CཱྀǎĿᯬ ปʸ′⍤ █ɳ SD ̓ তේǻ:2095-4344 ˈ֔ˊͼȸϣ ₓǜĚ ༘Ȍ࿆¾ (2017)33-05325-07 ปʸ′⍤ඈ˸྇ඝ(2) ۔ (2)࿆¾ඊྡྷ Oǎƌ ඊྡྷࢿΉdz ɘ4ěY2017-06-03 tปʸ′⍤ Ϗ ƅά͏ћ̓ 2 Ƨசɳ Ƨசɳ 2 ۔ ¾ඊྡྷඈɲ☝ (3)ྴှඈඋƮɍǜĚǎ࿆(3) ҉µƧ ͼȸ࿆¾ඊྡྷ ྴˏඊྡྷη̑Ρ ҉ õ:̺ (4)ǒɀඈ˸྇ඝtปʸ (4) ྴ ှ ඈ උ CXCL1 3 ҋǑà4 ′⍤ՈȐrɲ☝ͼȸ CXCL2 ǎ͢ǛĿ CXCR2 ࿆¾ඊྡྷ4 ᖏՁᜬẂˈ¿4 L₎5 ปʸ′⍤«P ÖZϬՈ̕Σx′ିሳĭ dzƅά┑ĺ 2 Ƨசɳ҉˯້Ոᜄசˈ¿ ᢧ̺ҋǑ à IJ⑃ƛūϬKĆȰႸཀྵྚʐˈྃ]ᄳǑà4 ¾ඊྡྷࢿΉ͏ћசɳ҉dz&ƶĿȴƇǷՈྴˏඈඋඊྡྷ ẟ໐ŻÏĿͱ>Ǜ4۸ūՈྴˏඈඋ ම࿆ ťǷՈᜄசˈ¿ ęû̺ҋǑà ᢧசɳ҉ՈÂǕҋ IJʌசɳʟȭ࿆¾ඊྡྷͣƅǃĐňϬ ƽˑ ࿆¾ඊྡྷࢿΉ͏ћՈάȘ4 ʼᡅ ëۘऺº߾ ʌசɳʟȭ࿆¾ඊྡྷƌϏͣƅºՈõ:ňϬ ẝPňϬₑƽˑ࿆¾ඊྡྷń 2 Ƨசྐ ɳ҉͏ћ5☦ՈάȘ4 Ƨசɳ҉ՈάȘ4 2 ۔Ոᢆȓปʸ′⍤༘Ȍ࿆¾ඊྡྷࢿΉ͏ћֲ̓ ỞẋွဘͼȸɃFₓ⏂◍༘۔Ǯ ╓ƶǚ 20 Ǯň&Ƿȭ+ඈ mŅՈ 88 Ǯ̓ 108 ۔̓ 5ͩǚ SD ˈ֔ˊ 4 ඈ͏ћµƧඈ˸྇ǎɲ☝ͼȸϣ Ȍʌசʌ࿆Ģņএ 2 Ƨசɳ҉µƧ ỤµȒ 20 d ╓ƶ ปʸ′⍤ඈ˸྇ඝtปʸ′⍤ ࿆¾ඊྡྷඈɲ☝ͼȸ࿆¾ඊྡྷ ǒɀඈ˸྇ඝtปʸ′⍤ՈȐ ाွᜄச3ྴˏ3Cཱྀ۔rɲ☝ͼȸ࿆¾ඊྡྷ4ţ 1 Ƶ/d Ảන͏ћ 7 d4͏ћȒ 3 ɬ ᢆȓȈඈ̓ ǎĿᯬₓǜĚ ࿆¾ඊྡྷ OǎƌϏ ྴှඈඋƮɍǜĚǎྴˏඊྡྷη̑Ρ Ñǎྴှඈඋ CXCL13 CXCL2 ǎ͢ǛĿ CXCR2 ᖏՁᜬẂˈ¿4 Ș^ ^Ƿȭ+ඈɨṇ µƧඈाွᜄசŋʌ(P < 0.05) ྴˏ3CཱྀǎĿᯬₓţ[┑(P < 0.05) ྴˏඊྡྷηϔₓʺ¤(P < 0.05) ྴှඈඋ CXCL13CXCL2 ǎ͢ǛĿ CXCR2 ᖏՁᜬẂŋʌ(P < 0.05) ྴ ˏඈඋƮɍ] ±ᢅɅₓྴˏඊྡྷþ ^µƧඈɨṇ ปʸ′⍤ඈ3࿆¾ඊྡྷඈ3ǒɀඈाွᜄச ┑ĺ(P < 0.05) ྴˏ3CཱྀǎĿᯬₓţŋʌ(P < 0.05) ྴˏඊྡྷηϔₓλɅ(P < 0.05) ྴှඈඋ CXCL13 CXCL2 ǎ͢ǛĿ CXCR2 ᖏՁᜬẂ┑ĺ(P < 0.05) ྴˏඈඋƮɍɌɴ]Ȑ࣏òΝΈ ͢ÑǒɀඈȈūʃǎ ྴˏඈඋΝΈ࣏òżº ࿆¾ඊྡྷඈ3ǒɀඈdzᢅࢿΉՈ࿆¾ඊྡྷ Ñǒɀඈɹ̶Șᜬ Ƨசɳ҉ õ:̺ҋǑà4 2 ۔ปʸ′⍤༘Ȍ࿆¾ඊྡྷࢿΉdzƅά͏ћ̓ ͟⏲᪑ ҋᱏĚüƄ̺۔ඊྡྷ࿆¾ඊྡྷปʸ′⍤ࢿΉசɳ҉̓¾ 'L᪑ ¾ඊྡྷசɳ҉ඊྡྷࢿΉඈඋ1࣏ Therapeutic effect of rosiglitazone combined with adipose-derived stem cell transplantation in rats with type 2 diabetes mellitus Kang Li-li, Attending Kang Li-li, Tian Meng (Department of Internal Medicine, Tianjin Jinnan District Xianshuigu Hospital, Tianjin 300350, physician, Department of China) Internal Medicine, Tianjin Jinnan District Xianshuigu Hospital, Tianjin 300350, Abstract China BACKGROUND: Studies have shown that high glucose environment has a significant inhibitory effect on the ISSN 2095-4344 CN 21-1581/R CODEN: ZLKHAH 5 3 2 5 Ƨசɳ҉ www.CRTER.org 2 ۔ăএ) . ปʸ′⍤༘Ȍ࿆¾ඊྡྷࢿΉ͏ћ̓ survival of adipose-derived stem cells, which significantly affects the therapeutic efficacy of adipose-derived stem cells on type 2 diabetes mellitus. OBJECTIVE: To investigate the therapeutic effect of rosiglitazone combined with adipose-derived stem cell transplantation in rats with type 2 diabetes mellitus. METHODS: A total of 108 male Sprague-Dawley rats were chosen, 20 of which were randomly taken as normal controls and the rest 88 rats were used to make type 2 diabetes mellitus models through intraperitoneal injection of low-dose streptozotocin combined with high-sugar/high-fat diet. At 20 days after modeling, the model rats were randomized into model, rosiglitazone, cell transplantation and combined groups, followed by administration of normal saline (by gavage and via tail vein), rosiglitazone (by gavage), adipose-derived stem cells (via tail vein), and rosiglitazone (by gavage)+adipose-derived stem cells (via tail vein), once a day, for consecutive 7 days. Three weeks after treatment, fasting blood glucose level, insulin level, C-peptide level, body mass changes were detected; distribution and survival of adipose-derived stem cells were observed; the changes of pancreas histomorphology was observed, the apoptosis in islet cells was detected, and the CXCL1, CXCL2 and CXCR2 protein expression levels in the pancreas tissue were determined. RESULTS AND CONCLUSION: Compared with the normal control group, the fasting blood glucose level was increased (P < 0.05), while the insulin level, C-peptide level and body mass were significantly decreased in the model group (P < 0.05); the number of apoptotic islet cells was increased (P < 0.05); the expression levels of CXCL1, CXCL2 and CXCR2 in the pancreas tissue were elevated (P < 0.05); and the pancreas tissue morphologies were in disorder, with few islet cell masses. Compared with the model group, the fasting blood glucose level was decreased (P < 0.05), while the insulin level, C-peptide level and body mass were significantly increased in the rosiglitazone, cell transplantation and combined groups (P < 0.05); the number of apoptotic islet cells was decreased (P < 0.05); the expression levels of CXCL1, CXCL2 and CXCR2 in the pancreas tissue were declined (P < 0.05); and the pancreas tissue morphologies were improved to different extents, and the combined group showed the best improvement. There were many transplanted adipose-derived stem cells in the cell transplantation and combined groups, especially in the latter one. Overall findings indicate that rosiglitazone combined with adipose-derived stem cell transplantation is an effective treatment for type 2 diabetes mellitus in rats, which is better to inhibit inflammations. Subject headings: Stem Cells; Diabetes Mellitus; Cell Transplantation; Tissue Engineering Cite this article: Kang LL, Tian M. Therapeutic effect of rosiglitazone combined with adipose-derived stem cell transplantation in rats with type 2 diabetes mellitus. Zhongguo Zuzhi Gongcheng Yanjiu. 2017;21(33):5325-5331. 0 šᣄ Introduction 1njʐ5ͩMaterials and methods Q ͔Аசɳ҉˯້>ॅ۸3.8«¦Ƶ ͢ę 1.1 Éα ╓ƶȭ+¬ĭǒɀ4ֲ ˯້ƅẕ1.3« சɳ҉>t&5྅¦ିɑăՈξˈǟͩ[1]4 1.2 ðϏΛıļ ǒɀz2015À8ƄႷ2016À10Ƅńͅ ͠]ᱷzňϬ ιĿ̓ƚ¬ĭǒɀۘऺȏǀt4 சɳ҉Ո҉ü'ᡅ«˯້ƶĿͱՈྴˏ Ǜ4└: ˯້Ո'ᡅ Öᜬɴ&ᜄசŋʌÂĠ╓]Ȑ 1.3 ƨ 108Ǯ Ŀᯬₓ220۔࣏òՈĿᯬₓλḿ[2]4᫇ɡ>ඓᜬ2Ƨசɳ҉ń¤ƅசɳ ǒɀ¬ĭ40 dܸ█ɳSD̓ ŤՈɨŷʌẂ90%ÑZ ᪩҉ₑƽˑ˯້ 260 g ϵͅιĿ̓ƚǒɀ¬ĭȏȴƇ ϣ᩼dz᪅ǻ¤້˯҉ ՈϣʁɑăʐϣϏᯬₓ[3]4ปʸ′⍤«ẕÀǡ ÖZṇ &SCXK(ι)2012-010 ¬ĭǒɀ᩼dz᪅ǻ&SYXK (ι) 80%3SPFɳʟ[Ⴎ ᢅՈPϬz͏ћ2Ƨசɳ҉Ոሳĭ ۘऺᜬ᪩ሳdz 2012-0026 ǘÕ25 ?3īò50%& ƅά┑ĺ2Ƨசɳ҉˯້Ոᜄசˈ¿ ᢧ̺ҋǑà IJ⑃ ϵĢˈʐ₋4 ¾ඊྡྷ(ͅιůϛϣĭ࿆۔ƛūϬKĆȰႸཀྵྚʐˈྃ]ᄳǑà[4-6]4Ⓒ̱ᯬ¾ඊྡྷ 'ᡅඊྡྷ3᪙FǎÖ ĚȈ࿁Ո̶࿁¾ඊྡྷ ẕÀǡ̶-ۘऺ 1࣏ƅ└͘Ǽ)ྴᖏՁ›(Sigma͘Ǽ)PBS3DMEMȕ Pିͣƅ̶ȕ» ǕɴⒸ̱ᯬ¾ඊྡྷdzdž^ǚ̩Ǜǃඈඋ[7-9] Âńசɳ҉š ͧȖ3ྒğᜄ±ʐPBS(Hyclone)ඊྡྷȕͧੵ(Heraeus ǕՈǃĐʐÂǕҋ͏ћ5☦ňϬºጛ[10-13]4࿆¾ඊྡྷň Sepatech ͘Ǽ)Trizol᪙F֖(Invitrogen)BCAᖏՁϧò Pļz࿆ඈඋՈⒸ̱ᯬ¾ඊྡྷ ẕÀ;ǛĿƚۘऺ ϟ᪙᪙F֖(ʺƆƧ)35×SDSᖏՁZʳΞ^320×TBS& └Ո☖ؔ[14-18]4ƅۘऺȘº߾ ࿆¾ඊྡྷńᢧ2Ƨச Ξ^(śņtϣĭ)᱉ά1ňǴ(ᄾ+ʌZ#᯼ƅ້ ɳ҉5☦ћάºጛ ͢'ᡅỞẋΝΈྴˏγͫɳ3ʺ¤ ͘Ǽ)CXCL13CXCL2ǎ͢ǛĿCXCR2Pû&̀û¦̶ βඊྡྷՈϔₓǡ┑ĺᜄச[19-20]4Ǹ̲ۘऺº߾ ʌசɳ ̷╊ûĿ CXCL13CXCL2ǎ͢ǛĿCXCR2Ոxû&ṧˏྴ ʟȭ࿆¾ඊྡྷՈƌϏͣƅºõ:ňϬ ẝPňϬₑ ʵẋʻĚĭ›(HRP)ʃᩴՈʥ๎û̶̷̀╊ûĿGAPDH û¦ûĿ GAPDHՈxû&HRPʃᩴ۔ƽˑ࿆¾ඊྡྷń2Ƨசɳ҉͏ћ5☦ՈάȘ[21]4üǸ Ȗ Pû&ř̷╊Ƀ Ո̶̷╊ûĿ(ᅂăϣĭäƫ(ǩ*)ƅ└͘۔zZẴۘऺ ᫂LඈȌϟỞẋปʸ′⍤Ո┑ᜄசňϬÑ Ոʥ๎ûɃ ȴʌ࿆¾ඊྡྷՈƌϏ࿁ ẟ໐ȴʌ࿆¾ඊྡྷࢿΉń2 Ǽ)4 Ƨசɳ҉Ո͏ћ5☦ՈάȘ Ñƛ&2Ƨசɳ҉Ո͏ћ1ň 1.4 ôκǒƽ ȴƇˊȋℸʐΓť4 1.4.1 ࿆¾ඊྡྷՈĿ̲ȕͧ ȺΧƌ࿆¾ඊྡྷาz 5326 P.O. Box 10002, Shenyang 110180 www.CRTER.org Ƨசɳ҉ www.CRTER.org 2 ۔ăএ) . ปʸ′⍤༘Ȍ࿆¾ඊྡྷࢿΉ͏ћ̓ 60 ?ʞÕˈ ੵ 30 sͱẟᜐȷợ̩ᆓ4ᙑĚ7ȒȺ࿆ ྡྷʃᩴɋ[22-24]4 ȏ̠̓⁍ٯඊྡྷẉ҂Ḱ͑EP¤͑DMEMȕͧȖ ₑ̩ɃȏȽ· ᆓƤஂ.ö൦ɏᄶᢆȓྴှඈඋƮɍǜĚ¾ ϔ10%϶ Ėǎྴှඈඋ ÂǚϦྴှඈඋ ϬĿࢳ۔ O ╓ȒࡿȏŏZ±^4Ⱥ̩ᆓȒՈඊྡྷϬ ඊྡྷū͢ţĄ DMEMǀ͔ȕͧȖ᫇Ϙ&1×109 L1Ոඊྡྷϧò4ẟᜐȕͧ3 :̣ྴှඈඋ ċūϬϵĺϧò4ʌϧòՈE⁋ňˈ ÏȒ ྴᖏՁ›Ţ^4Ě2.0 3.0 minȒඌǶ4ĚࡿȏŏZ F Ổ¼ƿඈඋųՈˈ 4Ⱥඈඋųาz^ŢzE ᗥՈồFx϶ᆳồ Ñx϶ᆳŻdžϦඈڷញႷ᪙ ⁋njŢz ₑ˸ඊྡྷ4᫇ϘඊྡྷϧòႷ1×109 L1± û¦ උųՈE⁋ ╓Ȓẟᜐ$ᗥĉǧ4ȺĉǧΙՈᗥųĖǎ۔mL/4 Ȉ¤͑5 µLȌƅ FITCzʃᩴՈɃ 0.1 CD343CD293CD443CD4453 CD903CD105řû 4 ? z ċƶZ t5 8 µmƞՈᑈċ4ȺᑈċΗ¿ 4 ὃ̵ƩĚ 30 minȒ ÑPBSΫP1Ƶ 1 000 r/minࡿȏ5 min ṁɿċZ 45 ?ʞÕ΄¾4ᗥȒ ẟᜐᆓƤஂö൦ɏ Ϭ500 µL PBSₑ˸ඊྡྷ ϕśඊྡྷÖ̼ϟỤᜄඊྡྷᜬ☦ʃᩴ ᄶ4ɏᄶȒՈ ċඓ൳E⁋ˈ ඓx϶ᆳū ċồ4 ċƠZ¤ţ̓ʍྺ ֚Z֚ɿċȵĖ4Ǒʍ ĭՈᜬẂ4 Ⱥ>ồՈ ှඈඋՈƮɍǜྴ۔ℸǎǀtȒ ࡿȏƿZ±ΫP Ⱥ࿆¾ඊྡྷϧò᫇ ྺ¾©Ȓ ራ̵ºǺ␠[ᢆȓȈඈ̓ Ϙ&8×108 L1 ╓Ȓȕඊྡྷ˸^¤͑5 µL CM-DiLʃᩴ Ě4 ǚྴှඈ۔30 minȒ ࡿȏŏZ TUNEL̼ͩϟྴˏඊྡྷη̑Ρ̠ȏ̓ ඊྡྷ╓ȒาzȕͧੵʃᩴƩĚ25 ċᢈᗥ ᗥڷ ċ͝ᩥϔ5 ှඈඋྴ۔PBSₑ˸ ₑ̩ʃᩴ2Ƶ ºǺ␠[ᢆȓඊྡྷʃᩴՈ̑ උ ɣǮ̓ ± Ρ4␠[dzᢅ࿆¾ඊྡྷʃᩴºɴϦѐᄷՈì൦ᄶhPᄶ ႷˈƠ¤1Ơ̩Ȍ4Ě^(ᖏՁ›K^྇ᖏՁ›) 25 ?Ʃ ţĄ ̣Ϭ4 Ě20 min ΫPȒƠ¤TUNELʃᩴǑà£Ȍ^50 µL ń ƶ ī֖37 ?Ʃྲྀ1 h Ơ¤POD2ḰĚ^50 µL ī֖ 37╓۔ඈ¾8 º108ǮSD̓ சɳ҉Ụµǎ 1.4.2 ö൦̩ Ảන₋7ɬՈʌ ?Ʃྲྀ30 min PBSΞΫ3Ƶ DABºᄶᆓƤஂ۔ọǚ20Ǯň&Ƿȭ+ඈ Ņ88ǮSD̓ ᄶඊྡྷʴՈඊྡྷ&ηඊྡྷ ᩥϔٸசʌ࿆Ģ(ʌ࿆ʌசĦȯ10%Ꮫச310%Ǯ͍ǎ5%ྊĖ ɏ ºǺ␠[dzᢅ͑ ⁋)7Ȓ Ảන3 dႮွဘͼȸɃFₓ⏂◍(45 mg/kg) ηඊྡྷϔₓÂᩥਜ਼ඊྡྷηɋ[25-26]4 ņএ2Ƨசɳ҉µƧ4ỤµȒ20 d ỞẋᜄசÖ̼ϟỤµ̓ Western blot̼ͩϟྴှඈඋCXCƧᱏĚüƄ‑Ŀ ۔Ոɲ☝ᜄ^Ոᜄசˈ¿ Ⱥ̼ϟȘϧඌÑȭ+Ոᜄ CXCL13CXCL2ǎ͢ǛĿCXCR2ᖏՁᜬẂˈ¿ǚ̓۔ சȨ(16.7 mmol/L)ň&ņµt£Ոʃβ4 ྴှඈඋ ʵǒBCA᪙F֖ȴǚÂϟǎྴှඈඋᖏՁϧò &4ඈ ɣඈ19 ໐ᣄ7Ⱥඊྡྷឆᢧ7ÂȺ7ࣄ₎ႷּȐՈᖏՁϧò ƶ╓۔Ⱥżඌņµt£Ո76ǮSD̓ ǮµƧඈ˸྇ඝtϣˊ֔ˈ1 mL ɲ☝ͼȸ1 mLϣˊ 100 ?2͌5 min ūᖏՁǜɳ4ɣඈǚᖏՁ40 µg 10% ปʸ′⍤ඈ˸྇ඝt4 mg/(kg࠽d)ปʸ′⍤(1 mL SDS-PAGEωྺϹ·(70 V 30 min100 V 90 min)Ḱˈ֔ ϣˊ֔ˈŢᢧ) ɲ☝ͼȸ1 mLϣˊ֔ˈ࿆¾ඊྡྷඈ ၠ(200 mA 3 h)ႷPVDFၠ5%࿆ğΒǘÕȵ⒱2 h(z ඝt1 mLϣˊ֔ˈ ɲ☝ͼȸ1 mL࿆¾ඊྡྷ˸^ 4 ?ẋ̸)Pû1a500 ǘÕƩྲྀ2 h (z4 ?ẋ̸)TPBS྇˸ (ඊྡྷϧò1×107 L1) ǒɀඈ˸྇ඝt4 mg/(kg࠽d)ปʸ ΫP3Ƶ PBSΫP1Ƶ7ȒẟᜐᖏՁ̹ѯŴẽՈǑà Ȍ ϟǎȈඈྴှඈඋ ⍤(1 mLϣˊ֔ˈŢᢧ) ɲ☝ͼȸ1 mL࿆¾ඊྡྷ˸ ı+ᩴơ7ȒẟᜐḳâՈĚʻ′ ^)¿ˈඊྡྷϧò1×107 L1)4ȈඈẢන¾87 d 1Ƶ/d4 CXCL13CXCL2ǎ͢ǛĿCXCR2ᖏՁᯬּȭᜬẂ)^ 1.5 ƶϙʬ+ŷ/ ͏ћȒ3ɬ ẟᜐÑ[̼ϟ4 β-actinՈ̜òࢳ ɨȨ) ň&CXCL13CXCL2ǎ͢ǛĿ ाွᜄச3ྴˏ3CཱྀǎĿᯬₓǜĚ̼ϟ CXCR2ᖏՁᜬẂՈₓ4۔̓ Ȍαǫʭ ¤ƅϔǒᰈՈඈⒸɨṇ₋Ϭřü 1.6 ۔ाွᜄசʐĿᯬₓǜĚ(ń̼ϟ7Q◄ᡅȭ̓۔Ȉඈ̓ _ Ȍ ǒɀȘÑx±sᜬ߾ Ո 5:(One-way ANOVA)࣏Û۔ẟᜐ12 hՈाွ̠ˊ)4ाွᜄசỞẋᜄசÖ̼ϟ̓ ဘ☝ ÂᢈǎP < 0.05&:Ŏƅºጛɳ͛54]۔z̓ ۔ɲ☝ᜄՈᜄசȯₓ ╓Ȓ̠ȏ̓ ཱྀ ाွྴˏʐC۔ġᜄ ₋ϬELISA᪙F֖ϟǎ̓ ˈ¿4 2ȘResults ራ̵ºǺ␠ᢆȓCM-Dil⓷ɳඊྡྷ OǎƌϏ₋▊̓ 2.1 ūǓȼˍFĝ́Ƨʬ+ ǒɀọǚĿ̲ȕͧႷP3Ï Ոϣ⑃v֟Ո࿆¾ඊྡྷ ΞĚ1¤߾ ৰ3Ï࿆¾ඊ ċÂẟᜐ4’ 6 ှඈඋΜΧྴ۔ှඈඋ :ň̓ྴ۔ x࿖Ȗ 2ᆳȖȶ˞ɏᄶ4¾©Ȓ ºǺ␠[ᢆȓr ╓ ྡྷȕͧYͅȒ ඊྡྷ¿⎾᱉ẋκá80%ÑZ ඊྡྷɌ ƶọǚɣŬΣΧ ċՈ3ᢊₒhȭ7ẟᜐı+ᩴơȳ ▊ጁʳϣ⑃ ʴº Ȁ±ì ƮɍĨt൨මʳඊ ᪂ɣŬ+ċՈʇò&1 ɣŬ+ċọǚP̵òͥ ྡྷ ඊྡྷᜬ☦̵Ž Oṇ&ţĄ dzᢅºǕMźՈ -ϬACDsee5.0ḳâܲǎ͢ŬʃȨ4ńĚʻ╓ƶọǚ8 ඊྡྷ̷╊ ƾඊྡྷȖƨ4͍Čৰ3ÏՈ࿆¾ඊྡྷºɴ ᢊₒ ᩥϔɣᢊₒ7CM-DilʃᩴՈ⓷ɳඊྡྷϔǎ ϦѐᄷՈì൦ᄶhPᄶţĄ4࿆¾ඊྡྷՈᜬ☦ʃᩴĭ ᢊₒ࿆¾ඊྡྷʇϔ Âᩥਜ਼ྴှඈඋՈ࿆¾ඊ ᜬẂ ᢅĚ24 ISSN 2095-4344 CN 21-1581/R CODEN: ZLKHAH 5327 Ƨசɳ҉ www.CRTER.org 2 ۔ăএ) .